作者: Garry Robert Smith , Allen B. Reitz
DOI:
关键词: Systemic circulation 、 Amyotrophic lateral sclerosis 、 Drug metabolism 、 Riluzole 、 Prodrug 、 Pharmacology 、 First pass 、 Medicine 、 Oral administration
摘要: Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for treatment amyotrophic lateral sclerosis (ALS) and related disorders through release riluzole, especially to avoid patient variability in first pass, hepatic metabolism promoted by Cyp 1A2. Pro-drugs have enhanced stability are delivered into systemic circulation oral administration, then cleaved plasma via either an enzymatic or general biophysical process. The further includes pro-drugs disease states that can be treated with from a pro-drug agent.